Washington

State

Medical

Oncology

Society


Home
About Us
Officers
Membership
Events
Newsletter
Corporate_Member_Events
Practice Issues
Resources
Contact Us
Member List
Legislative Update
Board Members - Password Required

MEMBERSHIP

Major benefits of your membership fee include the following:

National presence - WSMOS is represented on the ASCO Clinical Practice Committee and other major national initiatives of importance to oncology.

Advocacy in the state of Washington - WSMOS is active at the state level on issues of significance to the oncology community including the Medicare Carrier Advisory Committee.

Collaboration - WSMOS continues to be a liaison between our members and other groups that support the practice of oncology and the treatment of our patients.

Reimbursement - WSMOS is a leader in advocacy to state insurance carriers for medical reimbursement issues of concern to oncologists.

Education - WSMOS provides membership meetings which bring the socioeconomic issues and scientific advances in our discipline into the practical reality of our practice setting.

Web access - Unlimited access to the WSMOS website.

Publications - WSMOS members receive the WSMOS Newsletter, ACCC's Oncology Issues Newsletter and bi-weekly email updates and access to ACCC's member listserve. In addition, society members are listed on the WSMOS website.

Download the WSMOS Membership Application Forms Here:

Physician

Emeritus

Fellows

Administrator

Corporate Membership Opportunities

  Your support as a Corporate Member is vital to the continued advancement of WSMOS interests. With your support, WSMOS will continue to be the leading professional organization for oncologists in the state of Washington and a resource for the oncology community through professional education, and information dissemination. Click here to download information on WSMOS Corporate Membership.


Sanofi-aventis Announces Jevtana Approval

Sanofi-aventis is pleased to announce that on June 17, 2010, the US Food and Drug Administration (FDA) approved Jevtana® (cabazitaxel) Injection.

In addition, as of July 19, 2010, Jevtana is now commercially available.

Product related billing information is provided below:

  • National Drug Codes (NDCs)
    • NDC Assigned:    00024-5824-11       
    • Packaging: Carton of one (1) Jevtana vial & one (1) Diluent vial

  • HCPCS Codes
    • J9999     Not otherwise classified (NOC) antineoplastic drugs
    • C9399    Unclassified drugs or biologicals

For more information on Jevtana, please click here for full prescribing information, including boxed WARNING.

Updated VELCADE Label Announced

On January 4, 2010 Millennium announced that the FDA has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term overall survival data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. the VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM). Click Here to read the press release, Click Here to read the Physician Announcement Letter



 

 

 

 

 

 

 

 

 


 

 

This website brought to you by:

 

Washington State Medical Oncology Society
113 W. 7th Street Suite 205
Vancouver, Washington 98660
360.258.0443 Phone 360.695.6937 Fax
wsmos@comcast.net